INTRODUCTION {#s1}
============

Esophageal cancer ranks the ninth most common cancer and the sixth most common cause of cancer death worldwide \[[@R1]\]. Despite remarkable advances in the therapeutic strategy, extensive treatment may be associated with a noticeable decline in health-related quality of life and yet a poor prognosis \[[@R2]\]. Approximately 70% of global esophageal cancer cases occur in China, with esophageal squamous cell carcinoma (ESCC) being the histopathological form in the vast majority of cases (\> 90%) \[[@R3]\]. Alcohol consumption \[[@R4], [@R5]\], tobacco use \[[@R4], [@R6]\], poor oral hygiene, low socioeconomic status and nutritional deficiencies have been reported risk factors for esophageal cancer \[[@R7]--[@R10]\]. The fact that only a subset of cohort that are exposed to the risk factors eventually develop esophageal cancer suggested a critical role of genetic factors, including single nucleotide polymorphisms (SNPs), in the esophageal carcinogenesis.

Among all risk factors, others and we have repeatedly verified the indisputable role of alcohol consumption in the ESCC carcinogenesis \[[@R11], [@R12]\]. Extensive evaluations and reviews of alcohol-related cancers have been published in the Monographs of the International Agency of Research on Cancer (IARC) \[[@R13], [@R14]\], with most convincing evidence (Group I) for alcohol-drinking-related cancers is targeted on esophagus and some other organs \[[@R15]\]. Specific enzymes, whose activity and expression are influenced by genetic polymorphisms, regulate the metabolism of alcohol \[[@R11]\]. In humans, alcohol is primarily metabolized by two major groups of enzymes termed alcohol dehydrogenases (ADHs) and aldehyde dehydrogenases (ALDHs) \[[@R16]\]. In the cytosol of hepatocytes, ADHs catalyse the oxidation of ethanol to acetaldehyde, which is further oxidized to acetate by ALDHs in the mitochondria \[[@R11]\]. Although alcohol is not a carcinogen *per se*, its metabolite acetaldehyde is a toxin and carcinogen that rapidly binds to protein and DNA. It has profound effects on carcinogenesis by forming with DNA carcinogenic DNA adducts, by inhibiting DNA repair and by regulating DNA methylation. Acetaldehyde is degradated by ALDHs, which renders ALDHs a pivotal role in the carcinogenesis. Indeed, high ALDH1 expression predicts unfavorable outcomes in patients with ESCC \[[@R17]\]. Individuals with *ALDH2* Lys allele possess a higher risk of esophageal cancer, in correlation with a higher concentration of blood acetaldehyde after drinking alcohol \[[@R18]\]. There is a strong association between *ALDH2* Glu487Lys polymorphism and the risk of esophageal cancer \[[@R19]\]. *ALDH2* rs671 \[[@R20]\] and rs886205 \[[@R21]\] polymorphisms have also been demonstrated to correlate with ESCC, respectively.

Similarly, the aldehyde dehydrogenase 3 family member B2 (ALDH3B2) is also a key member of ALDH family. Originally identified as ALDH8, ALDH3B2 encodes a member of the aldehyde dehydrogenase family, a group of isozymes that may play a major role in the detoxification of aldehydes generated by alcohol metabolism and lipid peroxidation. As compared with ALDH1/2, little is known on ALDH3 family (including ALDH3B2) with respect to their roles in carcinogenesis. The association between ALDH3B2 polymorphisms and ESCC has not been investigated. Hence, in this hospital-based case-control study, we performed genotyping analyses of the seven SNPs in 1043 ESCC cases and 1315 controls in a Chinese population.

RESULTS {#s2}
=======

Characteristics of the study subjects {#s2_1}
-------------------------------------

The characteristics of the study subjects, including the demographics and environmental risk factors, are presented in Table [1](#T1){ref-type="table"}. The controls and cases were well matched in age and gender (χ^2^ test, *p* = 0.121 and 0.880, respectively). However, the cigarette-smoking rate (43.53% vs.26.70%, *p* \< 0.001) and alcohol drinking rate (31.54% vs.7.07%, *p* \< 0.001) were both significantly higher in the ESCC cases.

###### Distribution of selected demographic variables and risk factors in ESCC cases and controls

  Variable                    Cases (*n* = 1043)   Controls (*n* = 1315)   *p*             
  --------------------------- -------------------- ----------------------- ------- ------- --------------
  **Age (years) mean ± SD**   63.07(± 7.27)        62.88 (± 9.74)          0.607           
  **Age (years)**                                                                          
  \< 63                       471                  45.16                   636     48.37   
  ≥ 63                        572                  54.84                   679     51.63   0.121
  **Sex**                                                                                  
  Male                        758                  72.67                   952     72.40   
  Female                      285                  27.33                   363     27.63   0.880
  **Tobacco use**                                                                          
  Never                       589                  56.47                   964     73.30   
  Ever                        454                  43.53                   351     26.70   **\< 0.001**
  **Alcohol use**                                                                          
  Never                       714                  68.46                   1222    92.93   
  Ever                        329                  31.54                   93      7.07    **\< 0.001**

^a^ Two-sided *χ*^2^ test and student t test; Bold values are statistically significant (*p* \< 0.05).

As shown in Table [2](#T2){ref-type="table"}, the genotyping successful rates were all beyond 98.81%. In the control subjects, the genotype frequencies for the seven polymorphisms reached Hardy-Weinberg equilibrium (*p*-value for HWE, all *p* \> 0.05, Table [2](#T2){ref-type="table"}).

###### Primary information for *ALDH3B2* rs34589365, rs3741172, rs4646823, rs78402723, rs7947978, rs866907, rs9787887 polymorphisms

  Genotyped SNPs                              rs34589365       rs3741172                     rs4646823             rs78402723            rs7947978                             rs866907              rs9787887
  ------------------------------------------- ---------------- ----------------------------- --------------------- --------------------- ------------------------------------- --------------------- ----------------
  Ancestral Allele                            A                G                             G                     G                     C                                     A                     G
  Chromosome                                  11               11                            11                    11                    11                                    11                    11
  Gene (ID)                                   ALDH3B2(222)     ALDH3B2(222)                  ALDH3B2(222)          ALDH3B2(222)          ALDH3B2(222)                          ALDH3B2(222)          ALDH3B2(222)
  Function                                    intron-variant   reference, synonymous-codon   utr-variant-5-prime   utr-variant-3-prime   intron-variant, utr-variant-5-prime   utr-variant-3-prime   intron-variant
  Chr Pos (Genome Build 38.p7)                67668505         67663227                      67666945              67663118              67674572                              67663011              67673240
  Regulome DB Score^a^                        5                5                             4                     4                     4                                     4                     5
  TFBS^b^                                     Y                \--                           Y                     \--                   \--                                   \--                   \--
  nsSNP                                       \--              \--                           \--                   \--                   \--                                   \--                   \--
  MAF^c^ for Chinese in database              0.183            \--                           0.098                 0.058                 0.098                                 0.128                 \--
  MAF in our controls (n = 1315)              0.126            0.084                         0.105                 0.084                 0.105                                 0.105                 0.335
  *p* value for HWE^d^ test in our controls   0.110            0.784                         0.294                 0.808                 0.279                                 0.294                 0.258
  Genotyping method^e^                        LDR              LDR                           LDR                   LDR                   LDR                                   LDR                   LDR
  \% Genotyping value                         99.02%           99.02%                        99.02%                98.98%                99.02%                                99.02%                98.81%

^a^<http://www.regulomedb.org/>;

^b^TFBS: Transcription Factor Binding Site (<https://snpinfo.niehs.nih.gov/cgi-bin/snpinfo/snpfunc.cgi>);

^c^MAF: minor allele frequency;

^d^HWE: Hardy--Weinberg equilibrium;

^e^LDR: ligation detection reaction.

Associations between risk of ESCC and seven polymorphisms {#s2_2}
---------------------------------------------------------

As shown in Table [3](#T3){ref-type="table"}, the single locus analyses showed no statistically significant difference in genotype frequencies of seven SNPs between the cases and controls (*p* \> 0.05). As assessed by the allelic, dominant, co-dominant, recessive and Cochran-Armitage trend tests, there are no correlations between these seven polymorphism sites with the risk of ESCC (Table [3](#T3){ref-type="table"}).

###### Main effects of *ALDH3B2* SNPs on ESCC risk

  Locus              Geno-type   Case           Control         Co-dominant      Dominant         Recessive        Cochran-Armitage trend   Allelic test
  ------------------ ----------- -------------- --------------- ---------------- ---------------- ---------------- ------------------------ ----------------
  rs34589365 *A/G*   *AA*        13 (1.27%)     27 (2.06%)                                                                                  
                     *AG*        228 (22.24%)   275 (20.99%)    2.544; 0.2803    0.0678; 0.7945   2.147; 0.1429    0.0290; 0.8649           0.0294; 0.8639
                     *GG*        784 (76.49%)   1008 (76.95%)                                                                               
  rs3741172 *G/A*    *GG*        839 (81.85%)   1100 (83.97%)                                                                               
                     *AG*        176 (17.17%)   200 (15.27%)    1.906; 0.3855    1.828; 0.1764    0.3051; 0.5807   1.906; 0.1674            1.92; 0.1658
                     *AA*        10 (0.98%)     10 (0.76%)                                                                                  
  rs4646823 *G/T*    *GG*        15 (1.46%)     18 (1.37%)                                                                                  
                     *GT*        202 (19.71%)   239 (18.24%)    0.8581; 0.6511   0.8566; 0.3547   0.0330; 0.8559   0.7819; 0.3766           0.8008; 0.3709
                     *TT*        808 (78.83%)   1053 (80.38%)                                                                               
  rs78402723 *G/A*   *GG*        849 (82.91%)   1099 (83.89%)                                                                               
                     *AG*        166 (16.21%)   201 (15.34%)    0.4358; 0.8042   0.4023; 0.5259   0.0950; 0.7579   0.4343; 0.5099           0.4377; 0.5082
                     *AA*        9 (0.88%)      10 (0.76%)                                                                                  
  rs7947978 *C/A*    *CC*        804 (78.44%)   1054 (80.46%)                                                                               
                     *CA*        209 (20.39%)   238 (18.17%)    1.963; 0.3747    1.442; 0.2298    0.1874; 0.6651   0.9688; 0.325            0.9794; 0.3223
                     *AA*        12 (1.17%)     18 (1.37%)                                                                                  
  rs866907 *A/G*     *AA*        12 (1.17%)     18 (1.37%)                                                                                  
                     *AG*        204 (19.90%)   239 (18.24%)    1.171; 0.5568    0.7535; 0.3854   0.1874; 0.6651   0.4626; 0.4964           0.4686; 0.4936
                     *GG*        809 (78.93%)   1053 (80.38%)                                                                               
  rs9787887 *G/A*    *GG*        129 (12.63%)   156 (11.92%)                                                                                
                     *AG*        454 (44.47%)   565 (43.16%)    0.9959; 0.6078   0.9504; 0.3296   0.2748; 0.6001   0.9316; 0.3344           0.9567; 0.328
                     *AA*        438 (42.90%)   588 (44.92%)                                                                                

Stratification analyses on seven polymorphisms and risk of ESCC {#s2_3}
---------------------------------------------------------------

To further evaluate the effects of *ALDH3B2* rs34589365, rs3741172, rs4646823, rs78402723, rs7947978, rs866907 and rs9787887 on ESCC risk with different gender, age, smoking and alcohol drinking status, stratification analyses were performed as demonstrated in the Tables [4](#T4){ref-type="table"}--[10](#T10){ref-type="table"}.

###### Stratified analyses between *ALDH3B2* rs34589365 polymorphism and ESCC risk by sex, age, smoking status and alcohol consumption

  Variable              (case/control) ^a^   Adjusted OR ^b^ (95%CI); *p*                                                                                                                               
  --------------------- -------------------- ------------------------------ --------- ---------- ------ ------------------------------- ------------------------------- ------------------------------- -------------------------------
  Sex                                                                                                                                                                                                   
  Male                  12/19                554/717                        179/212   733/929    1.00   0.817 (0.39--1.70); *p*:0.588   0.748 (0.35--1.58); *p*:0.446   0.800 (0.39--1.66); *p*:0.547   0.934 (0.75--1.17); *p*:0.549
  Female                1/8                  230/291                        49/63     279/354    1.00   1.158 (0.02--1.27); *p*:0.085   0.161 (0.02--1.33); *p*:0.079   0.159 (0.02--1.28); *p*:0.085   1.122 (0.75--1.68); *p*:0.573
  Age                                                                                                                                                                                                   
  \< 63                 5/14                 347/478                        114/140   461/618    1.00   0.492 (0.18--1.38); *p*:0.239   0.439 (0.15--1.25); *p*:0.151   0.479 (0.17--1.34); *p*:0.168   0.939 (0.71--1.24); *p*:0.658
  ≥ 63                  8/13                 437/530                        114/135   551/665    1.00   0.746 (0.31--1.82); *p*:0.659   0.729 (0.29--1.82); *p*:0.497   0.746 (0.31--1.82); *p*:0.518   1.000 (0.76--1.31); *p*:0.999
  Smoking status                                                                                                                                                                                        
  Never                 8/21                 449/743                        117/196   566/939    1.00   0.630 (0.28--1.44); *p*:0.268   0.638 (0.27--1.49); *p*:0.295   0.632 (0.28--1.44); *p*:0.269   1.049 (0.82--1.35); *p*:0.706
  Ever                  5/6                  335/265                        111/79    446/344    1.00   0.659 (0.20--2.18); *p*:0.550   0.593 (0.18--2.01); *p*:0.533   0.643 (0.20--2.12); *p*:0.547   0.926 (0.67--1.28); *p*:0.642
  Alcohol consumption                                                                                                                                                                                   
  Never                 10/26                555/945                        138/246   693/1191   1.00   0.655 (0.31--1.37); *p*:0.257   0.686 (0.32--1.46); *p*:0.327   0.661 (0.32--1.38); *p*:0.267   1.079 (0.86--1.35); *p*:0.508
  Ever                  3/1                  229/63                         90/29     319/92     1.00   0.825 (0.08--8.07); *p*:1.000   0.967 (0.10--9.66); *p*:1.000   0.865 (0.09--8.42); *p*:1.000   1.173 (0.71--1.93); *p*:0.530

^a^The genotyping success rate was 99.02% for rs34589365; ^b^Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model; Fisher exact test was performed when *n* ≤ 5; Bonferroni correction was performed to correct the *p* value, bold values are statistically significant (*p* \< 0.0125).

###### Stratified analyses between *ALDH3B2* rs3741172 polymorphism and ESCC risk by sex, age, smoking status and alcohol consumption

  Variable              (case/control)^a^   Adjusted OR b (95%CI); *p*                                                                                                                               
  --------------------- ------------------- ---------------------------- --------- --------- ------ -------------------------------- ------------------------------- ------------------------------- --------------------------------
  Sex                                                                                                                                                                                                
  Male                  622/798             5/7                          118/143   123/150   1.00   1.091 (0.35--3.46); *p*:1.000    0.945 (0.72--1.23); *p*:0.674   0.951 (0.73--1.23); *p*:0.703   0.908 (0.29--2.87); *p*:1.000
  Female                217/302             5/3                          58/57     63/60     1.00   0.431 (0.10--1.82); *p*:0.291    0.706 (0.47--1.06); *p*:0.091   0.684 (0.46--1.02); *p*:0.059   2.176 (0.52--9.18); *p*:0.305
  Age                                                                                                                                                                                                
  \< 63                 387/527             4/8                          75/97     79/105    1.00   1.469 (0.44--4.91); *p*:0.770    0.950 (0.68--1.32); *p*:0.759   0.976 (0.71--1.34); *p*:0.882   0.675 (0.20--2.26); *p*:0.573
  ≥ 63                  452/573             6/2                          101/103   107/105   1.00   0.263 (0.05--1.31); *p*:0.149    0.804 (0.60--1.09); *p*:0.156   0.774 (0.58--1.04); *p*:0.090   3.667 (0.74--18.24); *p*:0.151
  Smoking status                                                                                                                                                                                     
  Never                 463/811             6/7                          105/142   111/149   1.00   0.666 (0.22--1.99); *p*:0.465    0.772 (0.59--1.02); *p*:0.067   0.766 (0.58--1.01); *p*:0.054   1.438 (0.48--4.30); *p*:0.513
  Ever                  376/289             4/3                          71/58     75/61     1.00   0.976 (0.22--4.39); *p*:1.000    1.063 (0.73--1.55); *p*:0.753   1.058 (0.73--1.53); *p*:0.765   1.035 (0.23--4.66); *p*:1.000
  Alcohol consumption                                                                                                                                                                                
  Never                 571/1024            7/9                          125/184   132/193   1.00   0.717 (0.27--1.94); *p*:0.509    0.821 (0.64--1.05); *p*:0.120   0.815 (0.64--1.04); *p*:0.100   1.350 (0.50--3.64); *p*:0.552
  Ever                  268/76              3/1                          51/16     54/17     1.00   1.175 (0.12--11.46); *p*:1.000   1.106 (0.60--2.05); *p*:0.748   1.110 (0.61--2.03); *p*:0.733   0.865 (0.09--8.42); *p*:1.000

^a^ The genotyping success rate was 99.02% for rs3741172; ^b^ Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model; Fisher exact test was performed when n ≤ 5; Bonferroni correction was performed to correct the *p* value, bold values are statistically significant (*p* \< 0.0125).

###### Stratified analyses between *ALDH3B2* rs4646823 polymorphism and ESCC risk by sex, age, smoking status and alcohol consumption

  Variable              (case/control) a   Adjusted OR b (95%CI); p                                                                                                                                  
  --------------------- ------------------ -------------------------- --------- ---------- ------ -------------------------------- -------------------------------- -------------------------------- -------------------------------
  Sex                                                                                                                                                                                                
  Male                  10/12              598/762                    137/174   735/936    1.00   1.062 (0.46--2.48); *p*:0.889    1.058 (0.44--2.52); *p*:0.898    1.061 (0.46--2.47); *p*:0.890    0.993 (0.78--1.26); *p*:0.954
  Female                5/6                210/291                    65/65     275/356    1.00   1.155 (0.35--3.83); *p*:1.000    0.833 (0.24--2.88); *p*:1.000    1.079 (0.33--3.57); *p*:1.000    0.732 (0.50--1.07); *p*:0.102
  Age                                                                                                                                                                                                
  \< 63                 5/11               373/506                    88/115    461/621    1.00   0.617 (0.21--1.79); *p*:0.450    0.594 (0.20--1.77); *p*:0.436    0.612 (0.21--1.77); *p*:0.450    0.999 (0.74--1.35); *p*:0.993
  ≥ 63                  10/7               435/547                    114/124   549/671    1.00   1.796 (0.68--4.76); *p*:0.232    1.554 (0.57--4.22); *p*:0.384    1.746 (0.66--4.62); *p*:0.255    0.840 (0.64--1.01); *p*:0.216
  Smoking status                                                                                                                                                                                     
  Never                 8/14               450/777                    116/169   566/946    1.00   0.987 (0.41--2.37); *p*:0.976    0.833 (0.34--2.05); *p*:0.689    0.955 (0.40--2.29); *p*:0.918    0.855 (0.66--1.04); *p*:0.229
  Ever                  7/4                358/276                    86/70     444/346    1.00   1.349 (0.39--4.66); *p*:0.764    1.424 (0.40--5.06); *p*:0.756    1.364 (0.40--4.70); *p*:0.764    1.032 (0.73--1.46); *p*:0.857
  Alcohol consumption                                                                                                                                                                                
  Never                 10/17              556/978                    137/222   693/1200   1.00   1.035 (0.47--2.28); *p*:0.932    0.953 (0.42--2.14); *p*:0.908    1.019 (0.46--2.24); *p*:0.963    0.924 (0.73--1.16); *p*:0.503
  Ever                  5/1                252/75                     65/17     317/92     1.00   1.488 (0.17--12.94); *p*:1.000   1.308 (0.14--11.95); *p*:1.000   1.451 (0.17--12.58); *p*:1.000   0.864 (0.48--1.54); *p*:0.620

^a^ The genotyping success rate was 99.02% for rs4646823; ^b^ Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model; Fisher exact test was performed when *n* ≤ 5; Bonferroni correction was performed to correct the *p* value, bold values are statistically significant (*p* \< 0.0125).

###### Stratified analyses between *ALDH3B2* rs78402723 polymorphism and ESCC risk by sex, age, smoking status and alcohol consumption

  Variable              (case/control)^a^   Adjusted OR^b^ (95%CI); *p*                                                                                                                               
  --------------------- ------------------- ----------------------------- --------- --------- ------ -------------------------------- ------------------------------- ------------------------------- --------------------------------
  Sex                                                                                                                                                                                                 
   Male                 629/798             4/7                           111/143   115/150   1.00   1.379 (0.40--4.73); *p*:0.764    0.985 (0.75--1.29); *p*:0.911   0.973 (0.75--1.27); *p*:0.837   0.727 (0.21--2.49); *p*:0.764
   Female               220/301             5/3                           55/58     60/61     1.00   0.439 (0.10--1.85); *p*:0.294    0.771 (0.51--1.16); *p*:0.210   0.743 (0.50--1.11); *p*:0.141   2.176 (0.52--9.18); *p*:0.305
  Age                                                                                                                                                                                                 
   \< 63                392/526             4/8                           70/98     74/106    1.00   1.490 (0.45--4.99); *p*:0.572    1.043 (0.75--1.46); *p*:0.803   1.068 (0.77--1.48); *p*:0.693   0.675 (0.20--2.26); *p*:0.573
   ≥ 63                 457/573             5/2                           96/103    101/105   1.00   0.319 (0.06--1.65); *p*:0.252    0.856 (0.63--1.16); *p*:0.315   0.829 (0.62--1.12); *p*:0.220   3.056 (0.59--15.81); *p*:0.255
  Smoking status                                                                                                                                                                                      
   Never                467/810             6/7                           101/143   107/150   1.00   0.673 (0.23--2.01); *p*:0.476    0.816 (0.62--1.08); *p*:0.154   0.808 (0.62--1.06); *p*:0.126   1.438 (0.48--4.30); *p*:0.513
   Ever                 382/289             3/3                           65/58     68/61     1.00   1.322 (0.27--6.60); *p*:1.000    1.179 (0.80--1.73); *p*:0.401   1.186 (0.81--1.73); *p*:0.377   0.776 (0.16--3.87); *p*:1.000
  Alcohol consumption                                                                                                                                                                                 
   Never                578/1023            7/9                           118/185   125/194   1.00   0.726 (0.27--1.96); *p*:0.526    0.886 (0.69--1.14); *p*:0.346   0.877 (0.69--1.12); *p*:0.297   1.350 (0.50--3.64); *p*:0.552
   Ever                 271/76              2/1                           48/16     50/17     1.00   1.783 (0.16--19.93); *p*:0.527   1.189 (0.64--2.21); *p*:0.585   1.212 (0.66--2.22); *p*:0.533   0.577 (0.05--6.43); *p*:0.535

^a^The genotyping success rate was 98.98% for rs78402723; ^b^Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model; Fisher exact test was performed when *n* ≤ 5; Bonferroni correction was performed to correct the *p* value, bold values are statistically significant (*p* \< 0.0125).

###### Stratified analyses between *ALDH3B2* rs7947978 polymorphism and ESCC risk by sex, age, smoking status and alcohol consumption

  Variable              (case/control) ^a^   Adjusted OR^b^ (95%CI); *p*                                                                                                                               
  --------------------- -------------------- ----------------------------- --------- --------- ------ -------------------------------- ------------------------------- ------------------------------- -------------------------------
  Sex                                                                                                                                                                                                  
   Male                 595/762              7/12                          143/174   150/186   1.00   1.339 (0.52--3.42); *p*:0.541    0.950 (0.74--1.22); *p*:0.683   0.968 (0.76--1.23); *p*:0.792   0.740 (0.29--1.89); *p*:0.527
   Female               209/292              5/6                           66/64     71/70     1.00   0.859 (0.26--2.85); *p*:1.000    0.694 (0.47--1.02); *p*:0.064   0.706 (0.49--1.03); *p*:0.068   1.079 (0.33--3.57); *p*:1.000
  Age                                                                                                                                                                                                  
   \< 63                372/507              4/11                          90/114    94/125    1.00   2.018 (0.64--6.39); *p*:0.295    0.929 (0.68--1.26); *p*:0.640   0.976 (0.72--1.32); *p*:0.872   0.489 (0.16--1.55); *p*:0.295
   ≥ 63                 432/547              8/7                           119/124   127/131   1.00   0.691 (0.25--1.92); *p*:0.476    0.823 (0.62--1.09); *p*:0.174   0.815 (0.62--1.07); *p*:0.143   1.392 (0.50--3.86); *p*:0.524
  Smoking status                                                                                                                                                                                       
   Never                447/778              7/14                          120/168   127/182   1.00   1.149 (0.46--2.87); *p*:0.766    0.824 (0.62--1.05); *p*:0.102   0.823 (0.64--1.06); *p*:0.134   0.834 (0.34--2.08); *p*:0.697
   Ever                 357/276              5/4                           89/70     94/74     1.00   1.035 (0.28--3.89); *p*:1.000    1.017 (0.72--1.44); *p*:0.923   1.018 (0.72--1.44); *p*:0.918   0.970 (0.26--3.64); *p*:1.000
  Alcohol consumption                                                                                                                                                                                  
   Never                552/979              9/17                          142/221   151/238   1.00   1.065 (0.47--2.41); *p*:0.879    0.878 (0.69--1.11); *p*:0.276   0.889 (0.71--1.12); *p*:0.313   0.915 (0.41--2.07); *p*:0.831
   Ever                 252/75               3/1                           67/17     70/18     1.00   1.120 (0.12--10.93); *p*:1.000   0.853 (0.47--1.54); *p*:0.597   0.864 (0.48--1.54); *p*:0.620   0.865 (0.09--8.42); *p*:1.000

^a^ The genotyping success rate was 99.02% for rs7947978; ^b^ Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model; Fisher exact test was performed when *n* ≤ 5; Bonferroni correction was performed to correct the *p* value, bold values are statistically significant (*p* \< 0.0125).

###### Stratified analyses between *ALDH3B2* rs866907 polymorphism and ESCC risk by sex, age, smoking status and alcohol consumption

  Variable              (case/control)^a^   Adjusted OR^b^ (95% CI); *p*                                                                                                                               
  --------------------- ------------------- ------------------------------ --------- ---------- ------ ------------------------------- ------------------------------- ------------------------------- -------------------------------
  Sex                                                                                                                                                                                                  
   Male                 7/12                598/762                        140/174   738/936    1.00   0.743 (0.29--1.90); *p*:0.534   0.725 (0.28--1.89); *p*:0.509   0.740 (0.29--1.89); *p*:0.527   0.993 (0.78--1.26); *p*:0.954
   Female               5/6                 211/291                        64/65     275/356    1.00   1.149 (0.35--3.82); *p*:1.000   0.846 (0.25--2.91); *p*:1.000   1.079 (0.32--3.57); *p*:1.000   0.746 (0.51--1.09); *p*:0.126
  Age                                                                                                                                                                                                  
   \< 63                4/11                373/506                        89/115    462/621    1.00   0.493 (0.16--1.56); *p*:0.295   0.470 (0.15--1.53); *p*:0.281   0.489 (0.16--1.55); *p*:0.295   0.999 (0.74--1.35); *p*:0.993
   ≥ 63                 8/7                 436/547                        115/124   551/671    1.00   1.434 (0.52--3.99); *p*:0.487   1.232 (0.43--3.51); *p*:0.695   1.392 (0.50--3.86); *p*:0.524   0.849 (0.64--1.12); *p*:0.245
  Smoking status                                                                                                                                                                                       
   Never                7/14                451/777                        116/169   567/946    1.00   0.861 (0.35--2.15); *p*:0.749   0.728 (0.29--1.86); *p*:0.506   0.834 (0.34--2.08); *p*:0.697   0.864 (0.67--1.12); *p*:0.262
   Ever                 5/4                 358/276                        88/70     446/346    1.00   0.964 (0.26--3.62); *p*:1.000   0.994 (0.26--3.84); *p*:1.000   0.970 (0.26--3.64); *p*:1.000   1.032 (0.73--1.46); *p*:0.857
  Alcohol consumption                                                                                                                                                                                  
   Never                9/17                557/978                        137/222   694/1200   1.00   0.930 (0.41--2.10); *p*:0.860   0.858 (0.37--1.98); *p*:0.719   0.915 (0.41--2.07); *p*:0.831   0.932 (0.74--1.17); *p*:0.551
   Ever                 3/1                 252/75                         67/17     319/92     1.00   0.893 (0.09--8.71); *p*:1.000   0.761 (0.07--7.78); *p*:1.000   0.865 (0.09--8.42); *p*:1.000   0.864 (0.48--1.54); *p*:0.620

^a^ The genotyping success rate was 99.02% for rs866907; ^b^ Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model; Fisher exact test was performed when *n* ≤ 5; Bonferroni correction was performed to correct the *p* value, bold values are statistically significant (*p* \< 0.0125).

###### Stratified analyses between *ALDH3B2* rs9787887 polymorphism and ESCC risk by sex, age, smoking status and alcohol consumption

  Variable              (case/control) ^a^   Adjusted OR^b^ (95%CI); *p*                                                                                                                               
  --------------------- -------------------- ----------------------------- --------- ---------- ------ ------------------------------- ------------------------------- ------------------------------- -------------------------------
  Sex                                                                                                                                                                                                  
   Male                 84/113               319/420                       338/414   657/834    1.00   0.979 (0.71--1.35); *p*:0.894   0.911 (0.66--1.25); *p*:0.562   0.944 (0.70--1.27); *p*:0.705   0.949 (0.78--1.15); *p*:0.593
   Female               45/43                119/168                       116/151   235/319    1.00   1.477 (0.92--2.39); *p*:0.110   1.362 (0.84--2.21); *p*:0.209   1.421 (0.91--2.23); *p*:0.126   0.854 (0.62--1.17); *p*:0.323
  Age                                                                                                                                                                                                  
   \< 63                63/83                203/287                       197/262   400/549    1.00   1.158 (0.80--1.67); *p*:0.433   1.090 (0.75--1.58); *p*:0.649   1.124 (0.80--1.59); *p*:0.506   0.939 (0.74--1.20); *p*:0.606
   ≥ 63                 66/73                235/301                       257/303   492/604    1.00   1.158 (0.80--1.68); *p*:0.442   1.066 (0.74--1.55); *p*:0.737   1.110 (0.78--1.58); *p*:0.563   0.909 (0.73--1.14); *p*:0.408
  Smoking status                                                                                                                                                                                       
   Never                76/107               245/430                       253/422   498/852    1.00   1.247 (0.89--1.74); *p*:0.194   1.241 (0.89--1.73); *p*:0.202   1.215 (0.89--1.66); *p*:0.223   0.916 (0.74--1.13); *p*:0.411
   Ever                 53/49                193/158                       201/143   394/301    1.00   0.885 (0.57--1.38); *p*:0.589   0.770 (0.49--1.20); *p*:0.246   0.826 (0.55--1.25); *p*:0.369   0.923 (0.70--1.22); *p*:0.579
  Alcohol consumption                                                                                                                                                                                  
   Never                91/141               305/552                       306/523   611/1075   1.00   1.168 (0.87--1.57); *p*:0.307   1.103 (0.82--1.49); *p*:0.520   1.136 (0.86--1.51); *p*:0.376   0.924 (0.77--1.11); *p*:0.409
   Ever                 38/15                133/36                        148/42    281/78     1.00   0.686 (0.34--1.38); *p*:0.291   0.719 (0.36--1.43); *p*:0.346   0.703 (0.37--1.35); *p*:0.285   1.132 (0.71--1.82); *p*:0.607

^a^ The genotyping success rate was 98.81% for rs9787887; ^b^ Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model; Fisher exact test was performed when *n* ≤ 5; Bonferroni correction was performed to correct the *p* value, bold values are statistically significant (*p* \< 0.0125).

Our analyses demonstrated that neither gender, age, cigarette smoking nor alcohol drinking has detectable impacts on the susceptibility of ESCC after stratified analyses.

Linkage disequilibrium analyses and association test {#s2_4}
----------------------------------------------------

Linkage disequilibrium analyses in both controls and cases were performed as shown in Tables [11](#T11){ref-type="table"}, [12](#T12){ref-type="table"} and Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}. There were strong correlations between these seven loci. Association test was conducted using Haploview software (version 4.2), strong associations were detected between these seven loci.

###### Linkage disequilibrium analyses of *ALDH3B2* rs34589365, rs3741172, rs4646823, rs78402723, rs7947978, rs866907 and rs9787887 in control group

  *D*'         rs3741172       rs4646823       rs78402723       rs7947978       rs866907       rs9787887
  ------------ --------------- --------------- ---------------- --------------- -------------- ---------------
  rs34589365   **0.991**       **0.993**       **0.992**        **0.993**       **0.993**      **0.977**
  rs3741172    \-              1               1                **0.995**       **1**          **1**
  rs4646823    \-              \-              1                **0.996**       **1**          **1**
  rs78402723   \-              \-              \-               **0.995**       **1**          **1**
  rs7947978    \-              \-              \-               \-              **0.996**      **0.993**
  rs866907     \-              \-              \-               \-              \-             **1**
  ***r*^2^**   **rs3741172**   **rs4646823**   **rs78402723**   **rs7947978**   **rs866907**   **rs9787887**
  rs34589365   0.013           0.017           0.013            0.017           0.017          0.272
  rs3741172    \-              **0.782**       **0.995**        **0.777**       **0.782**      0.182
  rs4646823    \-              \-              **0.786**        **0.988**       **1**          0.233
  rs78402723   \-              \-              \-               **0.781**       **0.786**      0.183
  rs7947978    \-              \-              \-               \-              **0.988**      0.229
  rs866907     \-              \-              \-               \-              \-             0.233

###### Linkage disequilibrium analyses of *ALDH3B2* rs34589365, rs3741172, rs4646823, rs78402723, rs7947978, rs866907 and rs9787887 in case group

  *D*'         rs3741172       rs4646823       rs78402723       rs7947978       rs866907       rs9787887
  ------------ --------------- --------------- ---------------- --------------- -------------- ---------------
  rs34589365   **0.984**       **0.982**       **0.983**        **0.979**       **0.981**      **0.969**
  rs3741172    **-**           **1**           **1**            **1**           **1**          **0.989**
  rs4646823    **-**           **-**           **1**            **0.985**       **1**          **0.957**
  rs78402723   **-**           **-**           **-**            **1**           **1**          **1**
  rs7947978    **-**           **-**           **-**            **-**           **1**          **0.974**
  rs866907     **-**           **-**           **-**            **-**           **-**          **0.991**
  **r2**       **rs3741172**   **rs4646823**   **rs78402723**   **rs7947978**   **rs866907**   **rs9787887**
  rs34589365   0.014           0.017           0.013            0.017           0.017          0.248
  rs3741172    \-              **0.828**       **0.943**        **0.824**       **0.845**      0.194
  rs4646823    \-              **-**           **0.78**         **0.966**       **0.981**      0.219
  rs78402723   \-              **-**           **-**            **0.776**       **0.796**      0.186
  rs7947978    \-              **-**           **-**            **-**           **0.976**      0.228
  rs866907     \-              \-              \-               \-              \-             0.231

![*D*\' \> 0, *r*^2^ \> 0: There were linkage disequilibrium correlations among different loci; *D*\' \> 70%, *r*^2^ \> 30%\
There were closer linkage disequilibrium correlations among different loci.](oncotarget-08-110153-g001){#F1}

![*D*\' \> 0, *r*^2^ \> 0: There were linkage disequilibrium correlations among different loci; *D*\' \> 70% (0.7), *r*^2^ \> 30% (0.3)\
There were closer linkage disequilibrium correlations among different loci.](oncotarget-08-110153-g002){#F2}

Haplotype analyses of ALDH3B2 polymorphisms and susceptibility of ESCC {#s2_5}
----------------------------------------------------------------------

As demonstrated in Table [13](#T13){ref-type="table"}, haplotype analyses showed that ALDH3B2 G~rs34589365~G~rs3741172~T~rs4646823~G~rs78402723~C~rs7947978~G~rs866907~A~rs9787887~ was most common haplotype in both groups (66.3% in controls, 64.6% in cases). As compared with G~rs34589365~G~rs3741172~T~rs4646823~G~rs78402723~C~rs7947978~G~rs866907~A~rs9787887~, none of the haplotypes was associated with the susceptibility of ESCC.

###### *ALDH3B2* haplotype frequencies (%) in cases and controls and risk of ESCC

  Haplotypes                                                                                       Case (freq)   Control (freq)   Crude OR(95% CI)        *p*
  ------------------------------------------------------------------------------------------------ ------------- ---------------- ----------------------- -------
  *ALDH3B2*A~rs34589365~G~rs3741172~T~rs4646823~G~rs78402723~C~rs7947978~G~rs866907~G~rs9787887~   247 (12.1)    323 (12.4)       1.007 \[0.840∼1.206\]   0.943
  *ALDH3B2*G~rs34589365~A~rs3741172~G~rs4646823~A~rs78402723~A~rs7947978~A~rs866907~G~rs9787887~   184 (9.0)     219 (8.4)        1.106 \[0.898∼1.363\]   0.344
  *ALDH3B2*G~rs34589365~G~rs3741172~T~rs4646823~G~rs78402723~C~rs7947978~G~rs866907~A~rs9787887~   1318 (64.6)   1735 (66.3)      1.000                   1.000
  *ALDH3B2*G~rs34589365~G~rs3741172~T~rs4646823~G~rs78402723~C~rs7947978~G~rs866907~G~rs9787887~   235 (11.5)    279 (10.6)       1.109 \[0.919∼1.338\]   0.281

Haplotypes were composited by *ALDH3B2* rs34589365, rs3741172, rs4646823, rs78402723, rs7947978, rs866907, rs9787887. All those frequency \< 3% were ignored in analysis, most common haplotype *ALDH3B2*G~rs34589365~G~rs3741172~ T~rs4646823~G~rs78402723~C~rs7947978~G~rs866907~A~rs9787887~ was selected as reference.

Power calculation {#s2_6}
-----------------

The power calculation was performed using the "Power and Sample Size Calculation" software (<http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize>). Based on the assumption that the type I error probability for a two sided test α equals 0.05, the probability of exposure in controls P~0~ is 0.126 in control. In the current study, using ligation detection reaction method, the successful rate of genotyping exceeded 98%. There were in total 1315 controls and 1043 cases successfully genotyped. The ratio of control/case (m) equals 1.261, and the correlation coefficient for exposure between matched case and controls (f) is 0.619. The power value is 0.936 as calculated by the "Power and Sample Size Calculation" software.

DISCUSSION {#s3}
==========

In this hospital-based case-control epidemiological study, we investigated the association between tagging SNPs of *ALDH3B2* and the risk of developing esophageal squamous cell carcinoma in a Chinese population. We found *ALDH3B2* rs34589365, rs3741172, rs4646823, rs78402723, rs7947978, rs866907 and rs9787887 polymorphisms were not implicated with altered susceptibility of ESCC according to age, gender, cigarette smoking and alcohol drinking stratification analyses.

Despite a suspected association between alcohol drinking and death to cancer reported in an epidemiological study as early as 1903, it took until 1988 for the research community to agree on the potential risk through the International Agency for Research on Cancer (IARC). Clear Patterns have emerged between alcohol consumption and esophageal cancer. Essentially, alcohol and its metabolite acetaldehyde were both designated as type 1A carcinogen \[[@R13]\]. The cytotoxic properties, the ability to form DNA-acetaldehyde adducts and to generate additional mutagenic species at concentrations attainable *in vivo* may underlie the carcinogenic effects \[[@R22]\]. Most of the acetaldehyde generated during alcohol metabolism *in vivo* is rapidly eliminated by aldehyde dehydrogenase (ALDH), which renders ALDH an important role in carcinogen balancing and therefore carcinogenesis. In fact, there is ample evidence showed that subjects with an inactive form of ALDH2 (heterozygous for ALDH2 mutation) have an increased risk of developing various types of head and neck cancers as a consequent of intense exposure to acetaldehyde. Case-control studies of various Japanese drinking populations \[[@R23]--[@R29]\] and Chinese alcoholics \[[@R30]\] have consistently reported that the inactive ALDH2 encoded by the ALDH2\*1/2\*2 genotype is a strong risk factor for esophageal cancer. In resemblance with ALDH2, ALDH3 also plays a pivotal role in the alcohol metabolism, we thus hypothesize that ALDH3 family may be of potential relevance to carcinogenesis. In line with our speculation, overexpression of ALDH3 protects cells from 4-hydroxynonenal induced apoptosis, suggesting a functional relevance of ALDH3 in the carcinogenesis. On the other hand, many of the sphere cells and stem cells reported in different organs have recently been found to be associated with elevated ALDH1A1 enzyme activity \[[@R31]--[@R33]\]. ALDH1A1 expression or activity may be used with other cell surface markers to identify tumor-initiating cells in hepatocellular, prostate and breast solid carcinomas \[[@R34]--[@R36]\]. ALDH1A1 has also been detected to be associated with early metastasis and poor clinical outcome \[[@R33]\]. In addition, the ALDH enzymes also play a pivotal role in epithelial homeostasis. Deregulation of these enzymes is associated with multiple cancers \[[@R37]--[@R41]\]. In the current study, we demonstrated that there are no significant association between ALDH3B2 SNPs and risk of ESCC for the first time. More importantly, we have analyzed the interaction of the genetic background and environmental risk factors. These findings indicate that ALDH3B2 may not be the primary contributor to ESCC carcinogenesis. Considering the biological function of ALDH3B2, the evaluation with combined considerations based on both genetic and environmental factors would be much more precise and meaningful.

Cigarette smoking and alcohol drinking have emerged as well-known risk factors of ESCC. Although *ALDH3B2* rs34589365, rs3741172, rs4646823, rs78402723, rs7947978, rs866907 and rs9787887 were not associated with the susceptibility of ESCC in the current study, the cigarette smoking rate and alcohol drinking rate were significantly higher in the ESCC cases, exemplifying the significance of interaction between the environmental and genetic risk factors in causing esophageal squamous carcinoma.

Our finding that there are more male than female subjects in the case group was in consistent with the comprehensive data recently published by the National Office for Cancer Prevention and Control as well as the National Cancer Center of China. The fact that smoking and alcohol drinking are far more prevalent in male subjects implicated the importance of these risk factors in carcinogenesis of ESCC.

One of the limitations of our previous studies investigating the association between SNPs and risk of ESCC was the sample size \[[@R12]\]. To overcome that, we have recruited a total of 2358 subjects including 1043 ESCC cases and 1315 controls in the current study. Yet, we do acknowledge there are still some limitations in this study. First, this study is limited by the sample sources, future studies designed and conduced in multiple ethnical populations and various geographic locations would be more convincing. Second, the lack of a validation cohort compromised the power of our study. Third, we are refrained by the lack of technical support to establish single nucleotide mutation cell/animal model, the actual biological function of these SNPs in esophageal carcinoma remains obscure, the underlying mechanisms are yet to be further dissected. Last but not least, the detailed information with regard to cancer metastasis and survival were not provided, the correlations between SNPs and outcomes have not been analyzed as this follow-up is still ongoing.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

This hospital-based case-control study was approved by the Review Board of Jiangsu University (Zhenjiang, China). All subjects provided written informed consents. This study has complied with the World Medical Association Declaration of Helsinki with regard to ethical conduct of research involving human subjects and/or animals.

Study populations {#s4_2}
-----------------

A total of subjects consisting of 1043 ESCC cases and 1315 non-cancer controls frequency-matched to the cases regarding age and gender (*p* = 0.121 and 0.880, respectively) were enrolled in this study (Table [1](#T1){ref-type="table"}). All patients and controls were consecutively recruited from the Affiliated People\'s Hospital of Jiangsu University (Zhenjiang, China) from October 2008 to January 2017. All cases of esophageal cancer were diagnosed as ESCC histologically. The exclusion criteria included cancer history, metastasized cancer or chemotherapy/radiotherapy history.

Each subject was individually questioned by experienced interviewers with a questionnaire to obtain information on demographic information and related risk factors (including alcohol consumption and cigarette smoking). After written informed consent was provided, two milliliters of venous blood were collected from each subject. The "Smokers" cohort included individuals who smoked one cigarette per day for more than one year. Subjects who had more than three alcoholic drinks a week for more than six months were included in the "Alcohol drinkers" cohort.

Genomic DNA extraction, SNP selection and genotyping {#s4_3}
----------------------------------------------------

Genomic DNA was isolated from peripheral blood using QIAamp DNA Blood Mini Kit (Qiagen, Berlin, Germany) as reported \[[@R12]\]. Sample DNA were amplified by PCR according to the manufacturer\'s protocol. Gene polymorphisms were analyzed by the ligation detection reaction (LDR) method with technical support from Genesky Biotechnology Inc. (Shanghai, China). 10% of the total samples were randomly selected for repeated analyses for quality control. Pilot linkage disequilibrium analyses were performed in the Chinese Han population to choose the SNP loci with moderate correlation, and tag SNPs were selected for further analyses.

Statistical analyses {#s4_4}
--------------------

Statistical analyses were conducted using SPSS 23.0 statistical package (SPCC Inc., Chicago, IL). Hardy-Weinberg equilibrium for genotypes was tested by goodness-of-fit χ^2^ in control group. Variations of demographic characteristics and genotypes of the *ALDH3B2* rs34589365, rs3741172, rs4646823, rs78402723, rs7947978, rs866907 and rs9787887 between the controls and cases were evaluated using the *chi*-square (χ^2^) test to examine the statistical differences. The associations between these seven SNPs and risk of ESCC were analyzed by PLINK software (v1.07, available at <http://zzz.bwh.harvard.edu/plink/download.shtml>). Crude ORs and adjusted ORs when adjusting for age, sex, smoking and alcohol drinking status were also computed using logistic regression analyses. Bilateral probability tests were taken, *p* value \< 0.05 was considered statistically significant.

CONCLUSIONS {#s5}
===========

The esophageal squamous carcinoma is associated with various factors including gene, environment and life-style. Our findings that *ALDH3B2* rs34589365, rs3741172, rs4646823, rs78402723, rs7947978, rs866907 and rs9787887 polymorphisms were not implicated with altered susceptibility of ESCC in different age, gender, cigarette smoking and alcohol drinking status, when interpreted with caution, could be helpful in evaluating the susceptibility to ESCC.
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